OBrien Christopher Flint 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Sep 7, 2017
Insider Transaction Report
Form 4
OBrien Christopher Flint
Sr. VP & Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2017-09-05$8.66/sh+52,817$457,395→ 101,790 total - Sale
Common Stock
2017-09-05$57.50/sh−52,817$3,036,978→ 48,973 total - Exercise/Conversion
Non-Qualified Stock Option
2017-09-05$8.66/sh−52,817$457,395→ 45,299 totalExercise: $8.66Exp: 2022-01-12→ Common Stock (52,817 underlying)
Footnotes (3)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $57.50 to $57.52. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Option granted January 12, 2012 and vested in 36 equal monthly installments.